SLC5A2 and diabetes mellitus: According to the statement by the American Diabetes Association (ADA) and the European Association for the study of Diabetes (EASD), SGLT2 inhibitors are currently integrated as second- or third-line therapy for the treatment of type 2 diabetes mellitus [6].